Regulus Therapeutics (RGLS) Tops Q4 EPS by 2c

Regulus Therapeutics (NASDAQ: RGLS) reported Q4 EPS of ($0.14), $0.02 better than the analyst estimate of ($0.16).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Sunstone Hotel Investors to sell Hyatt Regency San Francisco for $279M
• Deutsche Bank Starts DexCom (DXCM) at Buy